{"id":"zyprexa-olanzapine-5mg","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Weight gain"},{"rate":"10-20%","effect":"Dizziness"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Olanzapine, the active ingredient in Zyprexa, is an atypical antipsychotic that acts as a dopamine D2 and serotonin 5-HT2A receptor antagonist. This mechanism of action helps to reduce the symptoms of schizophrenia and bipolar disorder.","oneSentence":"Zyprexa works by blocking the action of dopamine and serotonin in the brain, which helps to reduce symptoms of psychosis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:33.255Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of schizophrenia"},{"name":"Treatment of bipolar disorder"}]},"trialDetails":[{"nctId":"NCT00647777","phase":"PHASE1","title":"Food Study of Olanzapine Tablets 5 mg and Zyprexa® Tablets 5 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2003-06","conditions":"Healthy","enrollment":32},{"nctId":"NCT00648921","phase":"PHASE1","title":"Fasting Study of Olanzapine Tablets 5 mg and Zyprexa® Tablets 5 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2003-06","conditions":"Healthy","enrollment":30},{"nctId":"NCT04075955","phase":"PHASE3","title":"Feasibility of Olanzapine at REduced doSe in hIGHly Emetogenic chemoTherapy","status":"COMPLETED","sponsor":"CR-CSSS Champlain-Charles-Le Moyne","startDate":"2019-04-29","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":30},{"nctId":"NCT03624322","phase":"PHASE1","title":"Safety and Tolerability of INP105 (Olanzapine by I231 POD® Device) Nasal Spray in Healthy Volunteers - SNAP 101","status":"COMPLETED","sponsor":"Impel Pharmaceuticals","startDate":"2018-08-05","conditions":"Acute Agitation","enrollment":38},{"nctId":"NCT01996488","phase":"PHASE1","title":"Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Olanzapine Orally Disintegrating 5mg Tablets Under Fasting Condition","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"","conditions":"Healthy","enrollment":""},{"nctId":"NCT01996501","phase":"PHASE1","title":"Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Olanzapine Orally Disintegrating 5mg Tablets Under Fed Condition","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"","conditions":"Healthy","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zyprexa®"],"phase":"phase_3","status":"active","brandName":"Zyprexa® (OLANZapine 5MG)","genericName":"Zyprexa® (OLANZapine 5MG)","companyName":"CR-CSSS Champlain-Charles-Le Moyne","companyId":"cr-csss-champlain-charles-le-moyne","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Zyprexa works by blocking the action of dopamine and serotonin in the brain, which helps to reduce symptoms of psychosis. Used for Treatment of schizophrenia, Treatment of bipolar disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}